Cytovance Biologics has revealed a strategic alliance with Contract Development and Manufacturing Organization (CDMO) Alcami Corporation, aimed at enhancing its capabilities in large molecule biologic manufacturing and sterile fill-finish services.
Positioned at the forefront of overcoming challenges in development and manufacturing, Cytovance specializes in refining unique processes to assist drug developers in achieving crucial milestones. Axel Schleyer, Cytovance's Chief Commercial Officer (CCO), expressed enthusiasm about merging Alcami's proficiency in liquid and lyophilization sterile filling, packaging, and labeling with Cytovance's bulk drug substance development and manufacturing services.
As an increasing number of drug targets emerge, many developers lacking internal manufacturing resources face challenges reaching clinical trials. This necessitates reliable CDMO partners to aid in achieving future commercialization goals. The key to successfully bringing complex products to market lies in collaborating with experienced experts with a proven track record of transforming molecules into bulk drug substances for patients in need.
The collaboration with Alcami expands Cytovance's offerings to include sterile fill-finish spaces, individual manufacturing and filling lines, and the option for customers to transition their bulk products to a trusted Current Good Manufacturing Practice (cGMP) partner for advanced clinical and commercial production and packaging. Alcami's services encompass formulation, release, and stability testing, vial and syringe filling, as well as advanced cGMP biostorage options that have supported the successful launch of over 50 commercial products.
Both companies are actively coordinating manufacturing processes and quality systems. Alcami CEO William Humphries emphasized their commitment to delivering unparalleled expertise in high-quality fill-finish operations during this crucial phase in complex large molecule drug development. This partnership marks Cytovance's third publicly announced collaboration this year, following two international partnerships with custom microbial strain development providers.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!